A malignitást fenntartó molekuláris mechanizmusokra irányuló gyógyszerek tervezése (Referátum)

Translated title of the contribution: Drug design against biopolymers contributing to the malignant progression

A. Jeney, I. Kovalszky, L. Kópper, J. Tímár, Babó István, Timár Ferenc, Pogány Gábor

Research output: Contribution to journalArticle

Abstract

In the last 10-15 years investigation on the molecular mechanism implicated in malignant progression has resulted remarkable changes in the strategy of tumour diagnosis and therapy. The present communication provides information about the pathobiological events which could be listed among the characteristic features of the malignant cells such as immortalisation, apoptosis, angiogenesis. The following molecular mechanisms contributing to these pathobiological events are considered as promising target for designing drugs to modulate the malignant phenotypes: protein-kinases, metalloproteinases, proteoglycans. The preclinical studies indicate that the chemical compunds inhibiting the activity of these biopolymers could control tumour cell viability, angiogenesis and metastasis formation. Nevertheless the clinical trials of these type of agents ret/uire novel strategy in terms of treatment schedule and estimation of their antitumour activity.

Original languageHungarian
Pages (from-to)55-60
Number of pages6
JournalMagyar Onkologia
Volume43
Issue number1
Publication statusPublished - 1999

Fingerprint

Biopolymers
Drug Design
Metalloproteases
Proteoglycans
Protein Kinases
Neoplasms
Cell Survival
Appointments and Schedules
Clinical Trials
Apoptosis
Neoplasm Metastasis
Phenotype
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

A malignitást fenntartó molekuláris mechanizmusokra irányuló gyógyszerek tervezése (Referátum). / Jeney, A.; Kovalszky, I.; Kópper, L.; Tímár, J.; István, Babó; Ferenc, Timár; Gábor, Pogány.

In: Magyar Onkologia, Vol. 43, No. 1, 1999, p. 55-60.

Research output: Contribution to journalArticle

@article{02c45570afab452fa755cb92b2d5a73a,
title = "A malignit{\'a}st fenntart{\'o} molekul{\'a}ris mechanizmusokra ir{\'a}nyul{\'o} gy{\'o}gyszerek tervez{\'e}se (Refer{\'a}tum)",
abstract = "In the last 10-15 years investigation on the molecular mechanism implicated in malignant progression has resulted remarkable changes in the strategy of tumour diagnosis and therapy. The present communication provides information about the pathobiological events which could be listed among the characteristic features of the malignant cells such as immortalisation, apoptosis, angiogenesis. The following molecular mechanisms contributing to these pathobiological events are considered as promising target for designing drugs to modulate the malignant phenotypes: protein-kinases, metalloproteinases, proteoglycans. The preclinical studies indicate that the chemical compunds inhibiting the activity of these biopolymers could control tumour cell viability, angiogenesis and metastasis formation. Nevertheless the clinical trials of these type of agents ret/uire novel strategy in terms of treatment schedule and estimation of their antitumour activity.",
author = "A. Jeney and I. Kovalszky and L. K{\'o}pper and J. T{\'i}m{\'a}r and Bab{\'o} Istv{\'a}n and Tim{\'a}r Ferenc and Pog{\'a}ny G{\'a}bor",
year = "1999",
language = "Hungarian",
volume = "43",
pages = "55--60",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A malignitást fenntartó molekuláris mechanizmusokra irányuló gyógyszerek tervezése (Referátum)

AU - Jeney, A.

AU - Kovalszky, I.

AU - Kópper, L.

AU - Tímár, J.

AU - István, Babó

AU - Ferenc, Timár

AU - Gábor, Pogány

PY - 1999

Y1 - 1999

N2 - In the last 10-15 years investigation on the molecular mechanism implicated in malignant progression has resulted remarkable changes in the strategy of tumour diagnosis and therapy. The present communication provides information about the pathobiological events which could be listed among the characteristic features of the malignant cells such as immortalisation, apoptosis, angiogenesis. The following molecular mechanisms contributing to these pathobiological events are considered as promising target for designing drugs to modulate the malignant phenotypes: protein-kinases, metalloproteinases, proteoglycans. The preclinical studies indicate that the chemical compunds inhibiting the activity of these biopolymers could control tumour cell viability, angiogenesis and metastasis formation. Nevertheless the clinical trials of these type of agents ret/uire novel strategy in terms of treatment schedule and estimation of their antitumour activity.

AB - In the last 10-15 years investigation on the molecular mechanism implicated in malignant progression has resulted remarkable changes in the strategy of tumour diagnosis and therapy. The present communication provides information about the pathobiological events which could be listed among the characteristic features of the malignant cells such as immortalisation, apoptosis, angiogenesis. The following molecular mechanisms contributing to these pathobiological events are considered as promising target for designing drugs to modulate the malignant phenotypes: protein-kinases, metalloproteinases, proteoglycans. The preclinical studies indicate that the chemical compunds inhibiting the activity of these biopolymers could control tumour cell viability, angiogenesis and metastasis formation. Nevertheless the clinical trials of these type of agents ret/uire novel strategy in terms of treatment schedule and estimation of their antitumour activity.

UR - http://www.scopus.com/inward/record.url?scp=84882935529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882935529&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84882935529

VL - 43

SP - 55

EP - 60

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -